|
As a fortune 500 multinational corporation operating in the healthcare sector, we are looking for certain new technologies to license or acquire. If you have technologies in these areas, we welcome you to get in touch via Tynax. We have the sales channels to effectively bring new healthcare products to market. We are keenly aware of and continuously review discoveries and developments across the entire drug discovery and development community. To achieve this, our Review and Licensing Committees, each target a specific therapeutic area or technology. This means that we provide a formal review and response for every viable opportunity. Areas of Interest: - New technology for measuring vascular compliance. - Markers of resopnder and/or nonresponder HTN populations. - Markers that link HTN to other metabolic syndrome phenotypes and/or atherosclerosis. - Markers for renal sequelae of HTN, including renal perfusion. - Markers for metabolic effects of diuretics. - Case/control cohorts for hypertension. Not Interested in: - Markers of CHF. |
